Breast Cancer

Data from the phase 2 TRIO-US B-12 TALENT trial indicate that fam-trastuzumab deruxtecan-nkxi in the neoadjuvant setting with or without endocrine therapy could be beneficial for patients with hormone receptor–positive, HER2-low breast cancer.

Yoga and conventional exercises also demonstrated long-term improvement in quality of life during treatment for non-metastatic breast cancer, according to results presented at the 2022 San Antonio Breast Cancer Symposium.

Experts believe that use of the Breast Cancer Index test in patients with early-stage, hormone receptor–positive breast cancer who are undergoing treatment with endocrine therapy may help to identify those who could be good candidates for the addition of ovarian function suppression.

The phase RIGHT Choice trial yield a 46% reduction in disease progression when ribociclib was added to endocrine therapy for patients with pre/perimenopausal hormone-receptor–positive/HER2-negative advanced breast cancer.

A racial disparity was determined when the tumor microenvironment of metastasis doorway density was found to be higher in Black women vs White women.

Non-Hispanic Black patients with HR+ breast cancer experienced worse overall outcomes compared with other patient subgroups despite similar recurrence scores, according to a recent analysis of the phase 3 RxPONDER trial.

Everolimus failed to improve survival outcomes when added to adjuvant endocrine therapy in patients with HR+/HER2- breast cancer, according to findings from the phase 3 SWOG S1207 trial.

The prespecified overall survival analysis of the phase 3 monarchE trial when abemaciclib was added to endocrine therapy in patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer.

Pre- and postmenopausal women with breast cancer may experience cognitive impairment with chemotherapy and endocrine therapy, which may return to baseline after 36 months.

Expert oncologists highlight remaining unmet needs in the setting of metastatic triple-negative breast cancer and look toward future evolutions in care.

Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.

Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.

Key opinion leaders Aditya Bardia, MD, MPH, and Alison Conlin, MD, provide a broad view of the current metastatic triple-negative breast cancer treatment landscape.

From shortening treatment duration without compromising efficacy in breast and prostate cancer to improving quality of life, experts share the main takeaways from the 2022 ASTRO Annual Meeting.

Income- and race-related disparities concerning supportive therapies for hormone receptor–positive breast cancer require further study to ensure equitable care and access for all patients, according to Melanie Wain Kier, MD, MBA.

Yancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.

A commentary on key takeaways from TROPiCS-02, remaining questions and unmet needs in the field, and the clinical implications of using SG and other Trop-2–directed ADCs in patients with HR+/HER2- mBC.

Drs Dietrich, Tolaney, and Vidal comment on PFS subgroup analyses, response rates, and common adverse events (AEs) observed in the TROPiCS-02 trial.

Findings from a retrospective cohort study indicated that radiotherapy treatment for breast cancer appeared to be a significant risk factor in developing thoracic soft tissue sarcoma.

Oral selective estrogen receptor degrader camizestrant elicited a statistically significant and clinically meaningful progression-free survival benefit compared with fulvestrant among patients with estrogen receptor–positive locally advanced or metastatic breast cancer.

Supplemental radiation doses delivered concomitantly with hypofractionated whole breast irradiation in 15 fractions demonstrated non-inferior ipsilateral breast recurrence and similar toxicity compared with sequential boosts following whole breast irradiation in high-risk early-stage breast cancer.

Among patients with advanced and/or metastatic hormone receptor–positive HER-2 negative breast cancer, complete estrogen receptor antagonist OP-1250 continued to yield clinical benefits such as reductions in target tumor lesions.

Dr. Joyce O’Shaughnessy closes the discussion with considerations for clinicians on monitoring patients with HER2-psotive breast cancer.

Experts discuss progression-free survival (PFS) and overall survival (OS) data from the TROPiCS-02 trial on SG versus treatment of physician’s choice.

Dr Tolaney discusses the TROPiCS-02 study design and comments on the key baseline characteristics of the patients with HR+/HER2- mBC who were enrolled in the trial.